BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) is considered one of the best stocks to buy under $20.
On October 1, BioCryst Pharmaceuticals announced the successful completion of the previously announced sale of its European ORLADEYO (berotralstat) business to Neopharmed Gentili.
The transaction is valued at $250 million upfront, subject to customary purchase price adjustments, with the potential for additional consideration.
https://ca.finance.yahoo.com/news/biocryst-sells-european-orladeyo-business-205450678.html